Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study.
Substance use, especially alcoholism, has been recognized as a significant problem in schizophrenic patients, though only a few studies on the effects of pharmacotherapy in these patients have been conducted so far. The thioxanthene neuroleptic flupenthixol, which can be given intramuscularly (i.m.) for improving compliance, has been studied as a possible anti-craving drug both in animal models of alcoholism and some clinical studies. Pilot studies suggest that comorbid schizophrenics with substance use may benefit from treatment with flupenthixol. Efficacy of flupenthixol (10-60 mg i.m.) in reducing alcohol consumption of dual diagnosis patients was studied in an open 6-month clinical trial in 27 schizophrenics with comorbid alcoholism. Twenty-one patients entered the intention-to-treat analysis. Fourteen subjects were completers, 13 dropped out. Six patients completely abstained from alcohol during treatment. Alcohol consumption was significantly reduced compared to baseline (4 weeks before treatment as measured by timeline follow-back interview). In general, while patients showed a marked improvement concerning alcohol consumption, only a slight improvement in psychopathology was recorded. Overall tolerability was good. These data indicate a probable beneficial effect of flupenthixol in schizophrenic patients with comorbid alcoholism. Although the efficacy of flupenthixol as an anti-craving drug in dual diagnosis patients has to be explored in further studies, the drug may be considered a promising medication for these patients.
Soyka
Michael
M
Psychiatric Hospital University of Munich, Munich, Germany. Michael.Soyka@psy.med.uni-muenchen.de
Aichmüller
Claus
C
v Bardeleben
Ulrich
U
Beneke
Manfred
M
Glaser
Thomas
T
Hornung-Knobel
Sybille
S
Wegner
Ulrike
U
D000328:Adult; D000437:Alcoholism / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation*; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D015897:Comorbidity; D017831:Diagnosis, Dual (Psychiatry); D005260:Female; D005475:Flupenthixol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005858:Germany; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts / Q000523:psychology / Q000706:statistics & numerical data; D012559:Schizophrenia / Q000453:epidemiology / Q000534:rehabilitation*; D012565:Schizophrenic Psychology; D013557:Switzerland; D016896:Treatment Outcome
D014150:Antipsychotic Agents; C007761:flupenthixol decanoate; D005475:Flupenthixol